37th week of 2012 patent applcation highlights part 39 |
Patent application number | Title | Published |
20120230953 | METHODS AND COMPOSITIONS FOR IMMUNOTHERAPY AND DETECTION OF INFLAMMATORY AND IMMUNE-DYSREGULATORY DISEASE, INFECTIOUS DISEASE, PATHOLOGIC ANGIOGENESIS AND CANCER - Methods and compositions for immunotherapy of inflammatory and immune-dysregulatory diseases are disclosed, using multispecific antagonists that target at least two different markers. The different targets are proinflammatory effectors of the innate immune system. The multispecific antagonists can be used to treat sepsis or septic shock. | 2012-09-13 |
20120230954 | Drug Comprising As The Active Ingredient Proliferative Vector Containing Survivin Promoter - It is intended to provide a drug to be used in gene therapy which specifically targets abnormal cells such as tumor cells and destroys the same for healing. Namely, a drug comprising, as the active ingredient, a proliferative vector which contains a Survivin promoter proliferating depending on the expression of Survivin. The drug may be used in order to treat tumor. In this drug, use may be made of an adenovirus as the vector. In the adenovirus of this drug, an endogenous promoter of an E1A domain may be substituted with a Survivin promoter. | 2012-09-13 |
20120230955 | ARABINOXYLANS FOR MODULATING THE BARRIER FUNCTION OF THE INTESTINAL SURFACE - The present invention is directed to a particular arabinoxylan (“AX”) preparation and the finding that this preparation has a beneficial effect on the organization of the intestinal microbial community in the lumen and in particular at the site of the gut mucosa, where it modulates the barrier function of the intestinal surface, primarily by modulating the mucosa-associated microbial community towards a relative increase of health beneficial bacteria, such as bifidobacteria and lactobacilli. It is accordingly a first aspect of the present invention to provide said arabinoxylan preparation characterized in comprising isolated water-soluble arabinoxylans and the use thereof to improve functioning (e.g. barrier function) of the intestinal epithelium. Thus, in a further aspect the present invention provides compositions, both pharmaceutical and nutritional compositions, comprising said arabinoxylan preparations; in particular pharmaceuticals, medical foods, food supplements or food compositions, such as infant formula products, dairy products, bakery products or pastry products. The compositions optionally comprise probiotics such as | 2012-09-13 |
20120230956 | BIFIDOBACTERIUM LONGUM AND FUNCTIONAL GI DISORDERS - The present invention generally relates to the field of probiotic bacteria. In particular it relates to | 2012-09-13 |
20120230957 | COMPOSITIONS AND METHODS FOR TREATMENT OF PAIN - The present invention provides compositions and methods for treatment or prevention of pain resulting from infection, infection related pain, and non-infectious pain as well as treatment or prevention of infections or adverse health consequences associated with infections. | 2012-09-13 |
20120230958 | ONCOLYTIC VACCINIA VIRUS COMBINATION CANCER THERAPY - Embodiments of the invention are directed methods that include a thymidine kinase deficient vaccinia virus. The methods include evaluating a tumor for reperfusion after treatment with vaccinia virus and administering an anti-angiogenic agent if reperfusion is detected. | 2012-09-13 |
20120230959 | ENHANCEMENT OF PLACENTAL STEM CELL POTENCY USING MODULATORY RNA MOLECULES - Provided herein are methods of producing enhanced placental stem cells by modulatory RNA molecules. Also provided herein are methods of using enhanced placental stem cells, for example, to treat individuals having a disease, disorder or condition caused by, or relating to, an unwanted or harmful immune response. Further provided herein are compositions comprising said enhanced placental stem cells. | 2012-09-13 |
20120230960 | PHARMACEUTICAL KITS COMPRISING MESENCHYMAL STEM CELLS - A method of treating a natural soft skeletal tissue injury in a patient the method comprising administering to the patient a composition of mesenchymal stem cells in liquid suspension enriched compared to the natural source of said cells, or tenocytes derived therefrom. The method is particularly suited to the regeneration of tendons in competitive mammals, such as the superficial digital flexor tendon of the horse. | 2012-09-13 |
20120230961 | MESENCHYMAL STEM CELL AND THE METHOD OF USE THEREOF - Demyelinated axons were remyelinated in the demyelinated rat model by collecting bone marrow cells from mouse bone marrow and transplanting the mononuclear cell fraction separated from these bone marrow cells. | 2012-09-13 |
20120230962 | GP100-SPECIFIC T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE - The invention provides human cells, particularly human T cells, comprising a murine T Cell Receptor (TCR) having antigen specificity for the cancer antigen gp100. Isolated or purified TCRs having antigenic specificity for amino acids 154-162 of gp100 (SEQ ID NO: 1), as well as related polypeptides, proteins, nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding fragments thereof, conjugates, and pharmaceutical compositions, are further provided. The invention further provides a method of detecting the presence of cancer in a host and a method of treating or preventing cancer in a host comprising the use of the inventive materials described herein. | 2012-09-13 |
20120230963 | Methods and Compositions for Expanding, Identifying, Characterizing and Enhancing Potency of Mammalian-Derived Glial Restricted Progenitor Cells - Methods for producing a population of human-derived glial restricted progenitor cells (GRPs) with decreased potentially unintended or undesired cellular phenotypes and/or decreased standard deviation in the cells of the population are provided. Also provided are antibody panels and gene expression profiles to characterize GRPs and a method for its use in characterizing GRP cells. In addition methods for use of these GRP cells to generate astrocytes and/or oligodendrocytes, to re-myelinate neurons and to treat glial cell related and other neurodegenerative diseases or disorders or injuries or damage to the nervous system are provided. A method to manufacture neural cells depleted of A2B5 positive cells is also provided. | 2012-09-13 |
20120230964 | THE ISOLATION AND CHARACTERISATION OF HEPARAN SULPHATES AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT AND STEM CELL CULTURE MEDIA SUITABLE FOR CONDITIONS ASSOCIATED WITH BONE REPAIR - Heparan sulphates isolated from male and female murine liver, their characterisation and use in pharmaceutical compositions, methods of treatment and in stem cell culture media suitable for conditions associated with bone repair. | 2012-09-13 |
20120230965 | Novel Microorganism Bacillus megaterium Toha Producing L-Type Poly-Gamma-Glutamic Acid and L-Type Poly-Gamma-Glutamic Acid Produced Thereby - The present invention relates to a novel microorganism producing L-type poly-gamma-glutamic acid and an L-type poly-gamma-glutamic acid produced thereby and, more particularly, to | 2012-09-13 |
20120230966 | TISSUE TRANSPLANT COMPOSITIONS AND METHODS FOR USE - Provided are transplants and methods for augmenting formation and restoration of organ and tissue, for example, bone formation, by administering autologous or allogeneic human embryonic-like adult stem cells (ELA cells). Also provided is a method for augmenting formation of tissues and organs by administering a transplant having ELA stem cells or combination of ELA stem cells. | 2012-09-13 |
20120230967 | DEVICE AND METHOD TO ACTIVATE PLATELETS - The present invention includes a method for activating platelets in a platelet solution, the method may include passing the platelet solution through an activator at least once to activate at least one of the platelets in the platelet solution to produce an activated platelet solution. The activator may further include a flow disruption element. The method may further induce administering the activated platelet solution to the repair site of a patient. The present invention may also be a system for treating a medical condition at a repair site within a patient in need thereof, which may include a platelet solution container for housing a platelet solution; an activator to activate at least one platelet; and an introducer to direct the at least one activated platelet to the repair site. | 2012-09-13 |
20120230968 | WOUND HEALANT SYSTEM AND METHODS OF USE - Provided herein are compositions for treating wounds, method of making and using the system thereof. The system for treating a wound includes a first composition having cetylpyridinium chloride, | 2012-09-13 |
20120230969 | METHOD AND PRODUCT FOR BLOOD TREATMENT AND PURIFICATION - Extracorporeal blood treatment is performed daily on a large number of patients by use of for example a dialysis filter, plasma filter or a centrifuge. The purpose of the treatment is to separate minor components and molecules in a liquid or in the blood from larger ones, for example in connection with different disease conditions or with a view to extracting blood plasma, target substances such as blood components or molecules from for example blood donors. According to the present invention two separation steps are used together with a solution or a suspension containing at least one component, which specifically may bind to the component or the blood component to be specifically reduced, or to be refined/extracted during the treatment or during the blood treatment. | 2012-09-13 |
20120230970 | METHOD FOR TREATING PERVASIVE DEVELOPMENT DISORDERS - A method of utilizing the chymotrypsin level of an individual as a measure of the success of secretin, other neuropeptides, and peptides or digestive enzyme administration to such individuals, and in particular, as a prognosticative of potential secretin, other neuropeptides, peptides, and digestive enzyme administration for persons having ADD, ADHD, Autism and other PDD related disorders. | 2012-09-13 |
20120230971 | CHROMOSOMAL MODIFICATION INVOLVING THE INDUCTION OF DOUBLE-STRANDED DNA CLEAVAGE AND HOMOLOGOUS RECOMBINATION AT THE CLEAVAGE SITE - Methods of modifying, repairing, attenuating and inactivating a gene or other chromosomal DNA in a cell are disclosed. Also disclosed are methods of treating or prophylaxis of a genetic disease in an individual in need thereof. Further disclosed are chimeric restriction endonucleases. | 2012-09-13 |
20120230972 | Salinosporamides and Methods for Use Thereof - The present invention is based on the discovery that certain fermentation products of the marine actinomycete strains CNB392 and CNB476 are effective inhibitors of hyperproliferative mammalian cells. The CNB392 and CNB476 strains lie within the family Micromonosporaceae, and the generic epithet | 2012-09-13 |
20120230973 | LACTASE PREPARATION - Disclosed is a lactase preparation which does not undergo the deactivation of lactase even when the preparation is ingested prior to the ingestion of a lactase-containing food or drink such as a milk product and therefore can decompose lactase stably and which can prevent the symptoms of lactase intolerance. Specifically disclosed is a lactase preparation comprising lactase and at least one component selected from trisodium citrate, potassium sodium tartrate, calcium carbonate, sodium carbonate and calcium hydrogen phosphate which acts as an antacid. The lactase preparation is characterized by being intended to be ingested prior to the ingestion of a lactase-containing food or drink to decompose lactase. In the lactase preparation, the antacid is contained at such a content per unit dosage form that the pH value in the stomach can be increased to 4 or higher after the ingestion of the preparation. | 2012-09-13 |
20120230974 | ALKALINE ALPHA GALACTOSIDASE FOR THE TREATMENT OF FABRY DISEASE - A method of treating Fabry is provided. The method comprises administering to a subject in need thereof a therapeutically effective amount of alkaline alpha galactosidase, thereby treating Fabry disease. | 2012-09-13 |
20120230975 | FUSION PROTEINS - A single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, or a fragment thereof, which protease or protease fragment can cleave a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a Targeting Moiety that can bind to a Binding Site on the nociceptive sensory afferent, which Binding Site can undergo endocytosis to be incorporated into an endosome within the nociceptive sensory afferent; a protease cleavage site at which site the fusion protein is cleavable by a protease, which is located between the non-cytotoxic protease and the Targeting Moiety; and a translocation domain that can translocate the protease or protease fragment from within an endosome, across the endosomal membrane and into the cytosol of the nociceptive sensory afferent; wherein the Targeting Moiety is BAM, β-endorphin, bradykinin, substance P, dynorphin and/or nociceptin. Nucleic acid sequences encoding the fusion proteins, methods of preparing same and uses thereof are also described. | 2012-09-13 |
20120230976 | ROTHIA SPECIES GLUTAMINE ENDOPEPTIDASES AND USE THEREOF - Disclosed are glutamine endopeptidase enzymes from | 2012-09-13 |
20120230977 | FLOWABLE COLLAGEN-BASED HEMOSTAT AND METHODS OF USE - The invention relates to hemostatic compositions and methods for promoting hemostasis. The invention also relates to hemostatic compositions and methods for promoting wound healing. In various embodiments, the hemostatic compositions comprise crosslinkable collagen molecules having a porosity controlled by the ratio of weight percent collagen solids to weight percent crosslinker when crosslinking the collagen. In other embodiments, the hemostatic compositions comprise crosslinkable collagen molecules having a porosity controlled by the temperature and rate of freezing when drying the composition during fabrication. In some embodiments, the compositions contain additional agents, including biological agents. | 2012-09-13 |
20120230978 | COMPOSITIONS AND METHODS FOR MODULATING CIRCADIAN SYNCHRONIZATION - The present invention relates to a modulator of glucocorticoid biosynthesis, degradation and/or receptor activation for use in preventing or treating symptoms and/or diseases associated with jet lag. The compositions of the invention may be used as a lead compound for developing a drug for preventing or treating symptoms and/or diseases associated with jet lag. The invention relates to the discovery that administration of the modulator(s) to a subject results in a directional change of the time point of maximum amounts of glucocorticoids in the subject as compared to the time point of maximum amounts of glucocorticoids in a subject not treated with the modulator(s). | 2012-09-13 |
20120230979 | NOGO Receptor Binding Protein - The invention provides Sp35 polypeptides and fusion proteins thereof, Sp35 antibodies and antigen-binding fragments thereof and nucleic acids encoding the same. The invention also provides compositions comprising, and methods for making and using, such Sp35 antibodies, antigen-binding fragments thereof, Sp35 polypeptides and fusion proteins thereof. | 2012-09-13 |
20120230980 | OPTIMIZED Fc VARIANTS AND METHODS FOR THEIR GENERATION - The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants. | 2012-09-13 |
20120230981 | CH2 Domain Template Molecules Derived From Rational Grafting Of Donor Loops Onto CH2 Scaffolds - Novel CH2 domain template molecules wherein donor loops from a database of domains are transferred to a CH2 domain scaffold. At least one or up to three loops from a donor are transferred to the CH2 domain. The donor loops may be chosen based on length, e.g., the donor loop may have a length that is similar to that of a structural loop in the CH2 domain scaffold. | 2012-09-13 |
20120230982 | HIGH CONCENTRATION ANTIBODY FORMULATIONS - The present disclosure relates to, inter alia, stable aqueous solutions comprising a high concentration of an antibody that binds to human complement component C5 and methods for preparing the solutions. The disclosure also provides methods for treating or preventing complement-associated disorders (for example, age-related macular degeneration or rheumatoid arthritis) using the solutions. Also featured are therapeutic kits containing one or more of the solutions and a means for administering the solutions to a patient in need such a treatment. | 2012-09-13 |
20120230983 | METHODS OF TREATING CANCER USING 3-(5-AMINO-2-METHYL-4-OXO-4H-QUINAZOLIN-3-YL)-PIPERIDINE-2,6-DIONE - Provided herein are methods of treating, preventing and/or managing cancers, which comprise administering to a patient 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione, or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof. | 2012-09-13 |
20120230984 | Methods of Treating or Preventing Autoimmune Diseases With 2,4-Pyrimidinediamine Compounds - The present invention provides methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds, as well as methods of treating, preventing or ameliorating symptoms associated with such diseases. Specific examples of autoimmune diseases that can be treated or prevented with the compounds include rheumatoid arthritis and/or its associated symptoms, systemic lups erythematosis and/or its associated symptoms and multiple sclerosis and/or its associated symptoms. | 2012-09-13 |
20120230985 | HUMANIZED ANTI-FACTOR D ANTIBODIES AND USES THEREOF - The invention relates to humanized anti-human Factor D monoclonal antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies are useful for diagnostics, prophylaxis and treatment of disease. | 2012-09-13 |
20120230986 | Agent and Methods for Reducing Inflammatory Markers - A method for treating an autism spectrum condition includes administering an effective dose of a TNF-α inhibiting agent to a person having an autism spectrum condition or pervasive development disorder and at least one of elevated TNF-α in the cerebrospinal fluid or elevated TNF-α in the serum, as compared to normal conditions; and lowering at least one of the elevated TNF-α in the cerebrospinal fluid or elevated TNF-α in the serum. A TNF-α inhibiting agent includes at least one of Lenalinomide; Thalidomide; L-Carnosine; Infliximab; Etanercept; a stem cell preparation; derivatives thereof, isomers thereof, or pharmaceutically acceptable salts thereof. | 2012-09-13 |
20120230987 | METHODS FOR TREATING CONDITIONS ASSOCIATED WITH C-FMS - Antigen binding proteins that bind to human c-fms protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of c-fms to CSF-1, reduce monocyte migration into tumors, and reduce the accumulation of tumor-associated macrophages. | 2012-09-13 |
20120230988 | ANTIBODY TARGETING OSTEOCLAST-RELATED PROTEIN SIGLEC-15 - To provide a method of detecting abnormal bone metabolism by using a gene strongly expressed in an osteoclast; a method of screening a compound having a therapeutic and/or preventive effect on abnormal bone metabolism; and a pharmaceutical composition for treating and/or preventing abnormal bone metabolism. Provision of a method of detecting abnormal bone metabolism by using the expression of human Siglec-15 gene as an index; a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation; and the like. | 2012-09-13 |
20120230989 | METHODS AND MATERIALS FOR TREATING RENAL CELL CARCINOMA - This document provides methods and materials related to treating renal cell carcinoma. For example, methods and materials for assessing a cancer patient (e.g., a renal cell carcinoma patient) for tumor or peritumoral tissue containing CD14 | 2012-09-13 |
20120230990 | HUMANIZED ANTIBODIES AGAINST HUMAN IL-22RA - The invention relates to humanized antibodies against human IL-22RA and to their use in the treatment of psoriasis and other immune-mediated diseases such as psoriatic arthritis and atopic dermatitis. | 2012-09-13 |
20120230991 | METHODS AND COMPOUNDS FOR ENHANCING ANTI-CANCER THERAPY - The invention provides methods of treating neoplastic disorders in a mammal through the inhibition of Mer and/or AxI receptor tyrosine kinases as well as compounds and compositions useful for inhibiting these kinases in these methods. These treatment methods may be combined with the administration of one or more chemo therapeutic agent(s) to enhance the efficacy or minimize the toxicities of the chemotherapeutic agent(s). | 2012-09-13 |
20120230992 | VEGF-RELATED PROTEIN - A human VEGF-related protein (VRP) has been identified and isolated that binds to, and stimulates the phosphorylation of, the receptor tyrosine kinase Flt4. The VRP is postulated to be a third member of the VEGF protein family. Also provided are antibodies that bind to VRP and neutralize a biological activity of VRP, compositions containing the VRP or antibody, methods of use, chimeric polypeptides, and a signal polypeptide for VRP. | 2012-09-13 |
20120230993 | AXL TYROSINE KINASE INHIBITORS AND METHODS OF MAKING AND USING THE SAME - Disclosed are novel inhibitors of the Axl receptor tyrosine kinase (RTK) and methods of using such inhibitors in a variety of therapeutic approaches in the areas of cancer therapy and anti-thrombosis (anti-clotting) therapy. | 2012-09-13 |
20120230994 | BLADDER CANCER SPECIFIC LIGAND PEPTIDES - The present invention is directed to bladder cancer specific ligand peptides, comprising the amino acid sequence X | 2012-09-13 |
20120230995 | POLYSPECIFIC BINDING MOLECULES AND USES THEREOF - The present invention relates to polyspecific binding molecules and particularly single-chain polyspecific binding molecules that include at least one single-chain T-cell receptor (sc-TCR) covalently linked through a peptide linker sequence to at least one single-chain antibody (sc-Ab). Further disclosed are methods and compositions for testing and using the molecules. | 2012-09-13 |
20120230996 | Compositions And Methods For Macular Degeneration - The present invention pertains to methods of inhibiting angiogenesis (e.g., ocular angiogenesis choroidal neovasculariztion) in an individual in need thereof comprising administering to the individual an agent that inhibits one or more CEP protein adducts wherein the angiogenesis is the result of 5 oxidative peptide modification of polyunsaturated fatty acids (PUFA) in the individual, and administration of the agent inhibits angiogenesis in the individual. | 2012-09-13 |
20120230997 | Anti-factor B antibodies and their uses - The invention concerns the prevention and treatment of complement-associated eye conditions, such as choroidal neovascularization (CNV) and age-related macular degeneration (AMD), by administration of factor B antagonists. | 2012-09-13 |
20120230998 | IP-10 ANTIBODIES AND THEIR USES - The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases. | 2012-09-13 |
20120230999 | BISPECIFIC NANOBODIES AS A THERAPEUTIC FOR ALZHEIMER'S DISEASE - The present invention provides for the treatment of Alzheimer's disease. More specifically, a recombinant bispecific antibody fragment that simultaneously blocks beta-secretase activity while also promoting alpha-secretase activity, comprising a first portion and a second portion, wherein the first portion blocks beta secretase activity and the second portion promotes alpha-secretase activity. | 2012-09-13 |
20120231000 | TRUNCATED CYSTINE-KNOT PROTEINS - The invention relates to the fields of protein chemistry, biology and medicine. More specifically, it relates to the design and preparation of proteinmimics of members of the cystine-knot growth factor superfamily. Further, the invention relates to the use of these proteinmimics as a medicament or prophylactic agent. The invention provides proteinmimics of members of the cystine-knot growth factor superfamily, preferably for use in immunogenic and/or therapeutic compositions. | 2012-09-13 |
20120231001 | PREVENTIVES/REMEDIES FOR CANCER - The present invention provides a drug containing a substance that inhibits a function of RET, such as an antibody against RET. In addition, the present invention provides a drug containing a substance that inhibits a function of GDNF, such as an antibody against GDNF. Moreover, the present invention provides a drug containing a substance that inhibits a function of GFRα1, such as an antibody against GFRα1. The drug of the present invention is useful as an agent for the prophylaxis or treatment of breast cancer and the like, an inhibitor of cancer cell growth and the like. | 2012-09-13 |
20120231002 | TREATMENT OF VASCULOPROLIFERATIVE CONDITIONS - This invention relates to the field of molecular physiology. Specifically, this invention relates to the prevention and/or treatment of vasculoproliferative conditions, especially those of the eye and in the treatment of tumours that exhibit vascular proliferation. Levels of leucine-rich alpha-2-glycoprotein (Lrg1) have been demonstrated to be increased in patients suffering from such conditions and animal models of such conditions. Antagonists of Lrg1 can be used to prevent and/or treat vasculoproliferative conditions. | 2012-09-13 |
20120231003 | Ox2 Receptor Homologs - Nucleic acids encoding mammalian, e.g., primate, receptors, purified proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are described. | 2012-09-13 |
20120231004 | ANTIBODIES - The present disclosure provides antibodies, including isolated monoclonal antibodies, which specifically bind to the Ephrin type-A receptor 10 with high affinity. Nucleic acid molecules encoding the Ephrin type-A receptor 10 antibodies, expression vectors, host cells and methods for expressing the Ephrin type-A receptor 10 antibodies are also provided. Bispecific molecules and pharmaceutical compositions comprising the Ephrin type-A receptor 10 antibodies are also provided. Methods for detecting the Ephrin type-A receptor 10, as well as methods for treating various cancers, including bladder cancer, breast cancer, colorectal cancer, head and neck cancer, kidney cancer, lung cancer, uterine cancer and pancreatic cancer are disclosed. | 2012-09-13 |
20120231005 | AX1 AND AX189 PSCK9 ANTAGONISTS AND VARIANTS - Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure. | 2012-09-13 |
20120231006 | ANTI-ORAI1 ANTIGEN BINDING PROTEINS AND USES THEREOF - Disclosed is an isolated antigen binding proteins, such as but not limited to, an antibody or antibody fragment, that specifically bind to SEQ ID NO: 4, the amino acid sequence of extracellular loop 2 (ECL2) of human Orai1. Also disclosed are pharmaceutical compositions and medicaments comprising the antigen binding protein, isolated nucleic acid encoding it, vectors and host cells useful in methods of making it, and methods of using it in treating disorders or diseases in patients. | 2012-09-13 |
20120231007 | MODULATORS OF CELL CYCLE PROGRESSION - Epithelial cell transforming sequence 2 (Ect2) is a potential oncogene. Our invention uncovers key mechanisms of Ect2 oncogenicity and the development of a relevant therapies by modulation of Ect2 expression. | 2012-09-13 |
20120231008 | Anti-C5A Binding Moieties with High Blocking Activity - The present invention relates to binding moieties that specifically bind to a conformational epitope of C5a, in particular human C5a. Preferred binding moieties are anti-C5a antibodies that bind to this conformational epitope. The binding moieties described herein are useful as active agents in pharmaceutical compositions for the treatment and prevention of various acute and chronic diseases, in particular acute inflammatory diseases, such as the systemic inflammatory response syndrome (SIRS), and different degrees of sepsis including sepsis, severe sepsis, and septic shock. | 2012-09-13 |
20120231009 | Formulations of Antibody - A stable pharmaceutically formulation containing antibody, a buffer, a non-ionic surfactant, and a lyoprotectants/cryoprotectants. Also disclosed are associated methods for preparing, storing, and using such formulations. | 2012-09-13 |
20120231010 | VINPOCETINE AND EBURN AMONINE DERIVATIVES FOR PROMOTING BONE GROWTH - The present invention provides a method of promoting bone growth in a subject in need thereof, by administering to the subject a therapeutically effective amount of a compound of Formula I. The compounds include the salts, hydrates and isomers thereof. The present invention also provides methods for the treatment of renal disease and cancer. | 2012-09-13 |
20120231011 | ANTI-VEGF MONOCLONAL ANTIBODY AND PHARMACEUTICAL COMPOSITION COMPRISING SAID ANTIBODY - The present invention provides an anti-VEGF monoclonal antibody, which has the variable region of heavy chain comprising the amino acid sequences of SEQ ID NO. 1, SEQ ID NO. 2 and SEQ ID NO. 3, and/or the variable region of light chain comprising the amino acid sequences of SEQ ID NO. 4, SEQ ID NO. 5 and SEQ ID NO. 6. The antibody can be produced by the cell line with the preservation number of CGMCC NO. 3233. The invention also provides the use of said antibody for the manufacture of medicaments for the treatment of a disease that is relevant to VEGF, wherein further provided are pharmaceutical composition, agents, kits and chips comprising said antibody, as well as the cell line with the preservation number of CGMCC NO. 3233. | 2012-09-13 |
20120231012 | Diagnosis, treatment, and prevention of vascular disorders using interleukin-1 autoantibodies - Method of detecting individuals at risk for atherosclerosis and related vascular diseases involving the detection of IL-1α autoantibodies, as well as therapeutic methods to prevent or treat atherosclerosis and related vascular disease by administering a pharmaceutical composition comprising IL-1α autantibodies. | 2012-09-13 |
20120231013 | POLYPEPTIDES THAT BIND TISSUE INHIBITOR OF METALLOPROTEINASE TYPE THREE (TIMP-3), COMPOSITIONS AND METHODS - The present invention relates to TIMP-3 binding compositions, methods of producing such compositions, and methods of using such compositions, including in the treatment of various conditions. | 2012-09-13 |
20120231014 | Neural Regeneration - A method of promoting neural cell regeneration is carried out by contacting a neural cell with a compound that inhibits the binding of a chondroitin sulfate proteoglycan (CSPG) to a cellular (e.g., trans-membrane) PTPσ protein. The neural cell is associated with an injury or neurodegenerative condition. | 2012-09-13 |
20120231015 | FRAGILE X MENTAL RETARDATION PROTEIN (FMRP), COMPOSITIONS, AND METHODS RELATED THERETO - The invention relates to fragile X mental retardation protein (FMKP), compositions, and methods related thereto. In certain embodiments, the invention relates to treating a neurological disorder by administering a P | 2012-09-13 |
20120231016 | Pharmaceutical Composition for Inhibiting Histone H4 and Manufacturing Method Thereof - The present invention discloses a pharmaceutical composition for inhibiting histone H4 and a manufacturing method thereof. The pharmaceutical composition comprises an anti-histone H4 antibody and a pharmaceutically acceptable excipient. The hair loss resulted from medications, including cancer drugs, can be reduced by using the pharmaceutical composition of the present invention, thereby resolving mental depression and promoting prognosis effects for patients. | 2012-09-13 |
20120231017 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS - Disclosed are compounds of the formula I | 2012-09-13 |
20120231018 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS - Disclosed are compounds of the formula I | 2012-09-13 |
20120231019 | FIBROSIS INHIBITOR - An objective of the present invention is to provide methods for treating or preventing fibrotic diseases, which are based on the novel finding that fibrosis is suppressed by administering ER-TR7 to a subject. | 2012-09-13 |
20120231020 | MARKERS FOR SELECTING PERSONALIZED THERAPIES FOR THE TREATMENT OF CANCER - The invention relates to the identification of aprataxin (APTX) expression levels as a marker for the response to topoisomerase I inhibitor-based therapies in patients with cancer and, more particularly, colon cancer. The invention also relates to methods for treating patients with cancer who have low APTX expression levels by means of administering a topoisomerase I inhibitor to said patients. | 2012-09-13 |
20120231021 | ANTIBODIES SPECIFICALLY BINDING TO THE EPIDERMAL GROWTH FACTOR RECEPTOR - Provided are antibodies specifically binding to the epidermal growth factor receptor (EGFR) which are effective for the treatment of EGFR-mediated cancers. | 2012-09-13 |
20120231022 | GLP-1 RECEPTOR AGONIST COMPOUNDS FOR SLEEP ENHANCEMENT - The disclosure provides, among other things, the use of GLP-1 receptor agonist compounds to enhance sleep, increase the duration and/or intensity of non-rapid eye movement (NREM) sleep, treat NREM sleep disorders, and to treat circadian rhythm sleep disorders. The GLP-1 receptor agonist compounds may be exendins, exendin analogs, GLP-1(7-37), GLP-1(7-37) analogs (e.g., GLP-1(7-36)-NH | 2012-09-13 |
20120231023 | Novel Vaccine Adjuvants Based on Targeting Adjuvants to Antibodies Directly to Antigen-Presenting Cells - The present invention includes compositions and methods for enhancing an immune response with an adjuvant composition comprising: an anti-dendritic cell (DC)-specific antibody or fragment thereof conjugated to at least a portion of Toll-Like Receptor (TLR) agonist, more specifically a TLR7 ligand (TLR7L), and a pharmaceutically acceptable carrier, wherein the conjugate and agonist are each comprised in an amount such that, in combination with the other, are effective to produce the immune response in a human or animal subject in need of immunostimulation. | 2012-09-13 |
20120231024 | MONOCLONAL ANTIBODIES AND SINGLE CHAIN ANTIBODY FRAGMENTS AGAINST CELL-SURFACE PROSTATE SPECIFIC MEMBRANE ANTIGEN AS DIAGNOSTIC AND THERAPEUTIC TOOLS FOR PROSTATE CANCER - Isolated monoclonal antibodies or an antigen binding portion thereof which bind to prostate specific membrane antigen in its native form occurring on the surface of tumor cells characterized in that it is linked to a label or a cytotoxic agent or constructed as a part of a bispecific antibody or a recombinant diabody. | 2012-09-13 |
20120231025 | Vaccine Having a Peptide Adjuvant for Eliciting a Specific Immune Response to Treat Viral Infection and Other Conditions - This invention provides a family of immunogenic compositions and vaccines, each containing a target antigen or antigen mixture, and an oligopeptide adjuvant, exemplified by the tripeptide Ile-Glu-Trp. The adjuvant has a low side effect profile, and may be especially effective in generating a rapid and specific Th1 or cellular immune response where the antigen is poorly immunogenic, or the patient is elderly or immunocompromised. In some circumstances, effectiveness of the vaccine can be substantially enhanced by administering follow-on injections of the tripeptide alone. The vaccine has been used to generate an enhanced response to multiple strains of influenza simultaneously, and is suitable for preventing or treating other infectious and disease conditions. | 2012-09-13 |
20120231026 | METHODS AND COMPOSITIONS FOR TUMOR VACCINATION AND THERAPY - The present invention relates to peptide vaccines, pharmaceutical compositions thereof, and associated methodologies that promote the immune-mediated regression of tumors expressing an onconeural antigen, e.g. a cdr-2 antigen, HuD antigen. The cancer peptide vaccines of the present invention are antigenic peptides capable of being faithfully presented on the MHC I complex of a target cell or antigen presenting cell. This external cellular presentation of these peptides promotes a specific cytotoxic T lymphocyte (CTL)-mediated immune response against tumor cells expressing these proteins, thereby, inducing immunological reactivity. | 2012-09-13 |
20120231027 | NOVEL H5 PROTEINS, NUCLEIC ACID MOLECULES AND VECTORS ENCODING FOR THOSE, AND THEIR MEDICINAL USE - The present invention relates to novel hemagglutinin H5 proteins, nucleic acids and vectors encoding for those as well as vaccines comprising any of such H5 proteins, nucleic acids or vectors encoding for those H5 proteins. Moreover, the present invention also relates to the medicinal use of any of such compositions in humans and animals. | 2012-09-13 |
20120231028 | POLYVALENT VACCINE - The present invention relates, in general, to an immunogenic composition (e.g., a vaccine) and, in particular, to a polyvalent immunogenic composition, such as a polyvalent HIV vaccine, and to methods of using same. The invention further relates to methods that use a genetic algorithm to create sets of polyvalent antigens suitable for use, for example, in vaccination strategies. | 2012-09-13 |
20120231029 | ENHANCED MALARIA MSP-1 SUBUNIT VACCINE - Recombinant subunit proteins derived from the MSP-1 C-terminal region of the parasite | 2012-09-13 |
20120231030 | MULTI-EPITOPIC VACCINE - The present invention relates to isolated polypeptides comprising: (i) a protein transduction domain consisting of ZEBRA or a fragment thereof that retains the capacity of internalization, (ii) at least one CD4 | 2012-09-13 |
20120231031 | COMPOSITION FOR IMPROVING LACTATION - Disclosed is a novel composition effective to improve lactation and milk production in an animal. In some embodiments the composition comprises a fiber-depleted fraction derived from fenugreek in combination with additives that synergistically improve the effective of the composition. Additives that enhance the effect of the fenugreek fraction can include apple cider vinegar, fennel seed powder, saw palmetto berry extract, kelp powder, and methylsulfonylmethane. | 2012-09-13 |
20120231032 | AGENT FOR EXPELLING PARASITES IN HUMANS, ANIMALS OR BIRDS - This invention relates to an agent which may be used to expel parasites from humans, mammals or birds. The agent of the invention may a vegetable product, | 2012-09-13 |
20120231033 | INACTIVATED POULTRY VACCINE - The present invention relates to pharmaceutical compositions comprising an immunizing amount of inactivated Newcastle disease and an adjuvant for use in the protection of poultry against Newcastle disease, to the use of an immunogenic amount of an inactivated Newcastle disease virus and an adjuvant for the manufacture of a booster vaccine for the vaccination of a chicken or turkey, and to a kit-of-parts comprises a container comprising an inactivated Newcastle disease virus and an adjuvant for a priming vaccination of a chicken or turkey and a container comprising an inactivated Newcastle disease virus and an adjuvant for a boosting vaccination of a chicken or turkey. | 2012-09-13 |
20120231035 | METHOD FOR INDUCING CELL LYSIS WITH IMMUNOGENIC PORTIONS OF NY-ESO-1 PROTEIN - The invention relates to peptides which bind to MHC Class I and to MHC Class II molecules. These peptides are useful in different therapeutic and diagnostic contexts. | 2012-09-13 |
20120231036 | CLONED BIOLOGICAL MATERIAL MEDICAL DEVICE AND METHOD THEREOF - A medical device, said medical device, comprises: a first component having a non-biological material; a second component having a cloned biological material, said second component being attached to said first component, wherein said first component and said second component are operatively associated in a non-living medical device for at least one of treatment, diagnosis, cure, mitigation and prevention of disease, injury, handicap or condition in a living organism. In another aspect, a method comprises: preparing a cloned biological material from a tissue or an organ; attaching said biological material to a medical device; interfacing said biological material with the non-biological material; providing treatment, diagnosis, cure, mitigation and prevention of disease, injury, handicap or condition in a living organism. | 2012-09-13 |
20120231037 | CRYSTALLINE DRUG-CONTAINING COATINGS - Articles-of-manufacturing comprising an object having a surface and a therapeutically active agent being deposited onto at least a portion of the surface, while at least a portion of said therapeutically active agent being in a crystalline form thereof are disclosed. Methods utilizing such articles-of-manufacturing for treating medical conditions are also disclosed. Processes of preparing the articles-of-manufacturing by contacting a surface of the object with a solution containing the therapeutically active agent; and cooling the surface to a temperature below a temperature of the solution, and apparatus for performing these processes, are also disclosed. | 2012-09-13 |
20120231038 | Wound Healing Compositions Comprising Biocompatible Cellulose Hydrogel Membranes and Methods of Use Thereof - The present invention provides a wound healing composition comprising a biocompatible hydrogel membrane wherein the hydrogel membrane has one or more of the following properties: high water content, high transparency, high permeability, high biocompatibility, high tensile strength and an optimal thickness. The invention further provides methods of treating a wound in a subject in need thereof, comprising contacting the wound with a biocompatible cellulose hydrogel membrane of the invention. | 2012-09-13 |
20120231039 | CHIMERIC IMMUNOMODULATORY COMPOUNDS AND METHODS OF USING THE SAME-IV - The invention provides immunomodulatory compounds and methods for immunomodulation of individuals using the immunomodulatory compounds. | 2012-09-13 |
20120231040 | CYSTEINE VARIANTS OF INTERLEUKIN-11 AND METHODS OF USE THEREOF - Disclosed are cysteine variants of interleukin-11 (IL-11) and methods of making and using such proteins in therapeutic applications. | 2012-09-13 |
20120231041 | Immunomodulating Nanoparticulate Composition - The present invention relates to a preferably nebulizable pharmaceutical composition comprising a pharmaceutically acceptable protein-based nanocarrier preferably in the size range 150 to 300 nm and a preventative or therapeutic amount of an active agent for use in the prevention and/or treatment of an allergic and/or inflammatory disease of the lower airways in a mammal. Preferably, the active agent is a CpG oligodeoxynucleotide (CpG-ODN), and preferably the composition exhibits a prolonged clinical effect. | 2012-09-13 |
20120231042 | Pharmaceutical Formulation For Producing Rapidly Disintegrating Tablets - Provided are pharmaceutical formulations in the form of granules comprising
| 2012-09-13 |
20120231043 | IMMOBILISED BIOLOGICAL ENTITIES - There is described inter alia a device having a surface comprising a layered coating wherein the outer coating layer comprises a plurality of cationic hyperbranched polymer molecules characterized by having (i) a core moiety of molecular weight 14-1,000 Da (ii) a total molecular weight of 1,500 to 1,000,000 Da (iii) a ratio of total molecular weight to core moiety molecular weight of at least 80:1 and (iv) functional end groups, whereby one or more of said functional end groups have an anti-coagulant entity covalently attached thereto. | 2012-09-13 |
20120231044 | VACCINE FORMULATION OF MANNOSE COATED PEPTIDE PARTICLES - A vaccine formulation as disclosed which is comprised of a pharmaceutically acceptable carrier in a plurality of particles with mannose on their surface. The particles are comprised of a biocompatible polymer which maybe a co-polymer such as PLGA combined with a peptide of a sequence which corresponds to a sequence on a surface of a pathogen. A plurality of different groups of particles are provided in the formulation wherein the particles within any single group include peptides of identical amino acid sequence. The particles are sized such that they are sufficiently large so as to prevent more than a single particle from being presented to a single immune system cell. | 2012-09-13 |
20120231045 | SUSTAINED RELEASE COMPOSITIONS OF ALFUZOSIN - The invention relates to sustained release compositions of alfuzosin or pharmaceutically acceptable salts thereof that include one or more functional layers. The functional layer includes alfuzosin or pharmaceutically acceptable salts thereof and one or more pharmaceutically acceptable hydrophilic and/or hydrophobic rate-controlling polymers. | 2012-09-13 |
20120231046 | IMPLANT FOR SUBCUTANEOUS OR INTRADERMAL INJECTION - The invention concerns an injection implant for filling up wrinkles, thin lines, skin cracks and scars, for reparative or plastic surgery, aesthetic dermatology, and for filling up gums in dental treatment. The invention concerns the use of biologically absorbable polymer microspheres or microparticles suspended in a gel. Said suspension is produced either ready-for-use or freeze-dried. The biological absorbability of the microspheres is controlled and enables the production of implants having well defined persistence and deliberately limited to 3 years. | 2012-09-13 |
20120231047 | THERAPEUTIC AGENT DELIVERY FOR THE TREATMENT OF ASTHMA VIA IMPLANTABLE AND INSERTABLE MEDICAL DEVICES - Methods for the treatment of asthma are provided, which comprise: (a) providing an implantable or insertable medical device that comprises an asthma treatment agent; and (b) inserting or implanting the medical device within the lungs (e.g., the trachea or the bronchial tree) of a patient, whereupon the therapeutic agent is delivered to the patient in an amount effective to reduce or eliminate the symptoms of asthma. Also disclosed herein are medical devices and kits for carrying out such methods. | 2012-09-13 |
20120231048 | Medical Devices and Implants from Nb-Ta-W-Zr Alloys - The present invention relates to a medical device or implant made at least in part of a high-strength, low-modulus metal alloy comprising niobium, tantalum, and at least one element selected from the group consisting of zirconium, tungsten, and molybdenum. The medical devices according to the present invention provide superior characteristics with regard to biocompatibility, radio-opacity and MRI compatibility. | 2012-09-13 |
20120231049 | Freeze-Thaw Method For Modifying Stent Coating - Methods are disclosed for controlling the morphology and the release-rate of active agent from a coating layer for medical devices comprising a polymer matrix and one or more active agents. The methods comprise exposing a wet or dry coating to a freeze-thaw cycle. The coating layer can be used for controlled delivery of an active agent or a combination of active agents. | 2012-09-13 |
20120231050 | Synthetic Lactone Formulations and Method of Use - Natural and synthetic compounds having a lactone structure methods for alleviation of pain, especially pain associated with disorders such as melanoma, leukemia, breast cancer, lung cancer, ovarian cancer, colon cancer, esophagus cancer, liver cancer, and lymphatic cancer. Initial studies have shown that patients can be taken off of morphine when the preferred alpha-methylene-gamma-butyrolactone is administered in a dosage of between 60 and 120 mg/day intramuscularly. | 2012-09-13 |
20120231051 | SINGLE UNIT ORAL DOSE PHARMACEUTICAL COMPOSITION COMPRISING LEVODOPA, CARBIDOPA AND ENTACAPONE OR SALTS THEREOF - There is provided a single unit oral dose pharmaceutical composition comprising a) levodopa or salts thereof from about 50 mg to about 300 mg in extended release form, b) carbidopa or salts thereof from about 10 mg to about 100 mg in extended release and c) entacapone or salts thereof from about 100 mg to about 1000 mg in immediate release form, optionally with other pharmaceutically acceptable excipients. The invention also relates to process of preparation of such compositions. | 2012-09-13 |
20120231052 | NEUROPROTECTION AND MYELIN REPAIR USING NESTORONE.RTM. - Methods for treating neurodegeneration and/or myelination in patients are disclosed comprising treating the patient with a progestin compound which exerts binding to progesterone receptors and elicits progesterone-receptor-induced biological responses without interacting with the androgen receptor and without inducing androgen or glucocorticoid biological responses at a dosage sufficient to prevent or reduce neurodegeneration. The progestin compound preferably comprises 16-methylene-17α-acetoxy-19-norpregn-4-ene-3,20-dione, and the methods include combining the progestin compound with an estrogen compound to provide both contraception and treatment for myelin repair and neurodegeneration. | 2012-09-13 |
20120231053 | Block Copolymer For Intraperitoneal Administration Containing Anti-Cancer Agent, Micelle Preparation Thereof, And Cancer Therapeutic Agent Comprising The Micelle Preparation As Active Ingredient - To provide a therapeutic method using a water soluble, high molecular weight block polymer to enable that an intraperitoneally administered anti-cancer agent may maintain for a long-term retention in the abdominal cavity to enoughly exert the effect of the anti-cancer agent and reduce adverse side-effects thereof. | 2012-09-13 |